查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2056465

mRNA疫苗和治療市場規模、佔有率、趨勢和預測：按疫苗類型、治療類型、疫苗生產商、應用、最終用戶和地區分類（2026-2034年）

mRNA Vaccines and Therapeutics Market Size, Share, Trends and Forecast by Vaccine Type, Treatment Type, Vaccine Manufacturing, Application, End-User, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 146 Pages | 商品交期: 2-3個工作天內

價格

2025年，全球mRNA疫苗和療法市場規模達605.8億美元。 IMARC Group預測，到2034年，該市場規模將達到751.1億美元，2026年至2034年的複合年成長率為2.30%。市場成長的促進因素包括全球對快速反應疫苗的需求不斷成長、癌症療法研發管線不斷擴大以及對脂質奈米顆粒（LNP）遞送技術的投資激增。

mRNA疫苗和療法利用人體細胞機制來引發免疫反應。 mRNA（傳訊RNA）是一種遺傳物質。在疫苗中，包括針對新冠病毒研發的疫苗，科學家設計了編碼特定病毒蛋白（稱為刺突蛋白）的mRNA片段。當這種mRNA被注射到體內後，會被細胞吸收，並透過指導產生相應的蛋白質來觸發免疫反應。

作為一種治療方法方法，mRNA技術不僅具有預防疾病的潛力，而且有望用於治療多種其他疾病。其高度的適應性和可程式設計性使其能夠快速且靈活地開發針對癌症和遺傳疾病等疾病的治療方法。透過設計mRNA來產生治療性蛋白質或糾正基因錯誤，它為以往難以治療的疾病帶來了新的希望。

mRNA疫苗和療法產業的主要驅動力是全球新冠疫情。疫情加速了mRNA疫苗在全球的研發和推廣，展現了該技術的有效性和快速擴充性。此外，對快速且適應性強的新興和再發感染疾病解決方案的需求也進一步推動了市場需求。由於mRNA疫苗的設計速度比傳統疫苗更快，該產業能夠有效地滿足這些需求。此外，癌症和遺傳性疾病發生率的不斷上升，以及mRNA療法在治療這些疾病方面的潛力，也促進了市場需求。

此外，生物資訊學、合成生物學和奈米顆粒遞送系統的持續進步，使得mRNA的設計和遞送更加高效，從而促進了產業成長。其他市場促進因素包括醫療基礎設施的不斷改進以及領先企業所進行的大量研發活動。

mRNA疫苗和治療藥物市場的趨勢和促進因素：

慢性疾病和感染疾病的發生率增加

隨著癌症、愛滋病和茲卡病毒等慢性疾病和感染疾病的日益增多，對創新治療性介入的需求顯著增加。 mRNA疫苗和療法具有獨特的能力，能夠引導人體自身產生治療性蛋白質，為應對多種疾病提供了新的途徑。

由於這些治療方法能夠從分子層面靶向疾病，因此它們有可能徹底模式轉移醫療保健的提供方式。因此，推動這些技術市場發展的不僅是這些疾病發生率的上升，還有醫療專業人員、患者和研究人員對基於mRNA的治療方法潛在益處的日益認可。

合成生物學和生物資訊學的進展

合成生物學和生物資訊學的快速發展在mRNA疫苗和療法的研發和改進中發揮了至關重要的作用。對基因組學的深入理解、基因編輯技術的進步以及利用複雜的計算模型預測mRNA結構和行為，都有助於更有效地設計和實施mRNA療法。這些進展也擴大了mRNA技術的潛在應用範圍，使其不再局限於感染疾病，而是涵蓋了遺傳性疾病和癌症等領域。隨著現代技術的應用範圍和有效性的不斷擴大，合成生物學和生物資訊學領域的持續進步正在進一步推動市場發展。

對個人化醫療的需求日益成長

個人化醫療旨在最佳化治療方法，使其更符合每位患者獨特的基因譜和健康需求。這種醫療模式標誌著醫療服務從單一模式轉向更多元化模式的重大轉變，近年來備受關注。 mRNA技術在這方面具有巨大的潛力，因為它能夠根據特定的基因譜或靶向特定的疾病突變來設計治療方案。

mRNA疫苗和治療方法的可自訂性提高了其療效和安全性，使其在個人化醫療領域極具吸引力。這推動了對個人化醫療的需求。隨著越來越多的醫療服務提供者和患者認知到個人化醫療的益處，對mRNA技術的需求不斷成長，進而影響市場。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 二手資訊
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：mRNA疫苗與治療藥物概述

  • mRNA疫苗及治療藥物研發史
  • 慢性病和主要感染疾病的發生率和盛行率
  • 利用mRNA疫苗和治療藥物進行預防和治療
    • mRNA修飾
    • mRNA效率
    • mRNA疫苗的佐劑、促效劑和載體技術
    • 基於mRNA的蛋白質和抗體治療載體

第6章：全球mRNA疫苗與治療市場

  • 市場潛力概述
  • 市場潛力
  • 新冠疫情的影響
  • 正在研發中的mRNA疫苗

第7章 市場區隔：依疫苗類型分類

  • 自擴增mRNA疫苗
  • 傳統非擴增mRNA疫苗

第8章 市場區隔：依治療類型分類

  • 基因治療
  • 單株抗體
  • 基因轉錄
  • 細胞療法
  • 生物工程疫苗
  • 其他

第9章 市場區隔：依疫苗生產商分類

  • 內部
  • 外包

第10章 市場區隔：依應用領域分類

  • 癌症
  • 感染疾病
  • 基因編輯
  • 蛋白質替代品

第11章 市場區隔：依最終用戶分類

  • 醫院和診所
  • 研究機構
  • 其他

第12章 市場區隔：依地區分類

  • 北美洲
    • 市場細分：按國家/地區
      • 美國
      • 加拿大
  • 歐洲
    • 市場細分：按國家/地區
      • 德國
      • 英國
      • 法國
      • 義大利
      • 西班牙
      • 俄羅斯
      • 其他
  • 亞太地區
    • 市場細分：按國家/地區
      • 日本
      • 中國
      • 澳洲
      • 韓國
      • 印度
      • 印尼
      • 其他
  • 拉丁美洲
    • 市場細分：按國家/地區
      • 巴西
      • 墨西哥
      • 其他
  • 中東和非洲
    • 市場細分：按國家/地區

第13章 SWOT 分析

第14章：價值鏈分析

第15章：波特五力分析

第16章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • Moderna, Inc.
    • BioNTech SE
    • Pfizer Inc.
    • GSK plc
    • Arcturus Therapeutics
    • Sanofi
    • Merck & Co.
Product Code: SR112026A2207

The global mRNA vaccines and therapeutics market reached a value of USD 60.58 Billion in 2025. IMARC Group expects the market to reach USD 75.11 Billion by 2034, exhibiting a CAGR of 2.30% during 2026-2034. Market growth is driven by rising global demand for rapid-response vaccines, expanding oncology pipelines, and surging investment in lipid nanoparticle (LNP) delivery technologies.

mRNA vaccines and therapeutics leverages the body's own cellular machinery to generate an immune response. mRNA, or messenger RNA, is a type of genetic material. In the context of vaccines, including those developed for COVID-19, scientists design a small piece of mRNA that codes for a specific viral protein, known as the spike protein. When injected, this mRNA enters cells and instructs them to produce this protein, triggering an immune response.

As a therapeutic approach, mRNA technology can be potentially used to treat various diseases, not just prevent them. It's adaptable, programmable nature offers a fast and flexible method for creating treatments for conditions including cancer or genetic disorders, where the mRNA can be designed to produce therapeutic proteins or to correct genetic errors, offering new hope for previously untreatable conditions.

The mRNA vaccines and therapeutics industry is primarily driven by the outbreak of COVID-19 across the globe. This has encouraged the development and acceptance of mRNA-based vaccines on a global scale, demonstrating the effectiveness and rapid scalability of this technology. Along with this, the need for quick and adaptable solutions for emerging and re-emerging infectious diseases further fuels demand. As mRNA vaccines can be designed faster than traditional vaccines, this industry is positioned to address this need effectively. Additionally, the growing incidence of cancer and genetic diseases and the potential of mRNA therapeutics to treat these conditions.

In addition, continuous advancements in bioinformatics, synthetic biology, and nanoparticle delivery systems are enabling more efficient design and delivery of mRNA, contributing to the industry's growth. Some of the other factors driving the market include continual improvements in healthcare infrastructure and extensive research and development activities conducted by key players.

mRNA Vaccines and Therapeutics Market Trends/Drivers:

Growing Incidence of Chronic and Infectious Diseases

With the rise of chronic and infectious diseases such as cancer, HIV, and Zika, there has been a considerable increase in the need for innovative therapeutic interventions. mRNA vaccines and therapies are unique in their ability to instruct the body to produce its own therapeutic proteins, offering a novel approach to tackling a wide range of diseases.

As these treatments can target diseases at a molecular level, they represent a potential paradigm shift in how healthcare is provided. The market for these technologies is thus driven by the rising incidence of these diseases, as well as the increasing recognition among healthcare providers, patients, and researchers of the potential benefits of mRNA-based treatments.

Advancements in Synthetic Biology and Bioinformatics

The rapid pace of advancements in synthetic biology and bioinformatics has been instrumental in the development and refinement of mRNA vaccines and therapeutics. An improved understanding of genomics, enhanced capabilities in gene editing, and the use of sophisticated computational models to predict mRNA structure and behavior have all contributed to the more effective design and delivery of mRNA therapies. These advancements also expand the potential applications of mRNA technologies beyond infectious diseases to include genetic disorders and cancers, among others. The market is further driven by continual improvements in the fields of synthetic biology and bioinformatics due to the increasing scope and efficacy of modern technologies.

Rising Demand for Personalized Medicine

Personalized medicine aims to tailor treatments to the individual patient's unique genetic profile and health needs. This approach to healthcare represents a significant departure from the one-size-fits-all paradigm and has been gaining traction in recent years. mRNA technologies hold significant promise in this regard due to their inherent ability to be designed for specific genetic profiles or to target specific disease variants.

This potential to customize mRNA vaccines and treatments is improving their therapeutic efficacy and safety profile, making them particularly attractive in the context of personalized medicine. This is propelling the demand for personalized medicine. As more healthcare providers and patients become aware of the benefits of personalized medicine, the demand for mRNA technologies is escalates, thereby impacting the market.

mRNA Vaccines and Therapeutics Industry Segmentation:

The research provides an analysis of the key trends in each segment of the global mRNA vaccines and therapeutics market report, along with forecasts at the global, regional and country levels from 2026-2034. Our report has categorized the market based on vaccine type, treatment type, vaccine manufacturing, application, and end-user.

Breakup by Vaccine Type:

  • Self-amplifying mRNA-Based Vaccines
  • Conventional Non-Amplifying mRNA-Based Vaccine.

Conventional non-amplifying mRNA-based vaccines dominate the market

The growing global health concerns about emerging infectious diseases and the need for quick vaccine development are majorly driving the market segment. These vaccines can be quickly produced and modified, making them ideally suited for combatting rapidly mutating diseases such as influenza and COVID-19. Additionally, the recent success of mRNA vaccines is leading to an increased acceptance and trust in this technology, influencing the market demand. Along with this, the rising prevalence of cancer, and the potential of mRNA vaccines for cancer treatment, also act as a significant market driver. Moreover, continual technological advancements and significant investments in research and development of mRNA technology play a crucial role in shaping the market.

The market for conventional non-amplifying mRNA-based vaccines has also seen rapid growth due to the acceptance and adoption of mRNA technology, demonstrating its ability to rapidly develop effective vaccines against novel pathogens. This has led to increased investment in mRNA research and development, and growing confidence in its potential. Additionally, the relatively quick and cost-effective production process of mRNA vaccines, as well as their versatility for targeting a variety of diseases.

As diseases evolve and new pathogens emerge, the capacity for rapid design modifications is becoming an increasingly important market driver. Besides, there is a rising focus on personalized medicine, and mRNA vaccines have the potential to be tailored to individual patient needs, such as for cancer immunotherapy, providing another strong growth driver in the market.

Breakup by Treatment Type:

  • Bioengineered Vaccine
  • Gene Therapy
  • Gene Transcription
  • Cell Therapy
  • Monoclonal Antibody
  • Other.

Bioengineered vaccine dominate the market

Bioengineered vaccines' ability to be quickly designed and mass-produced in response to new viral threats positions them as a vital tool in global health security, fostering increased investment and demand. In addition, the ongoing research exploring the potential of mRNA therapeutics beyond vaccines, such as in cancer immunotherapy and genetic diseases, broadens the industry's scope. Moreover, policy support from governments and collaborations between pharma-biotech companies contribute to the acceleration of mRNA-based research, development, and commercialization.

On the other hand, the broad therapeutic potential of gene therapies for a wide array of genetic, oncologic, and chronic diseases are expected to augment the growth of the segment. Technological advancements in gene editing tools, including CRISPR-Cas9, have facilitated the development and refinement of mRNA-based gene therapies. The growing prevalence of genetic disorders and the urgent need for effective treatments have also spurred interest and investment in this sector. Besides this, favorable government policies, increased healthcare expenditure, and strategic collaborations among biotech and pharmaceutical companies accelerate this industry's growth.

The market for gene transcription in the mRNA vaccines and therapeutics industry is further fueled by the creation of innovative treatment modalities for various diseases. Along with this, advancements in genomics and transcriptomics technology are enhancing our ability to manipulate and understand gene transcription, further driving the market. In addition, the rise in the prevalence of diseases, including cancer, where abnormal gene transcription plays a key role, necessitates continued investment and exploration in this field.

Breakup by Vaccine Manufacturing:

  • In-House
  • Out-Source.

In-house manufacturing dominate the mRNA vaccines and therapeutics market

The potential of mRNA technologies to treat a broad array of diseases beyond infectious diseases, including cancer, is acting as a catalyst for companies to invest in their own manufacturing capabilities. The need for supply chain security and independence, the desire to control quality standards, and the potential cost savings over time through economies of scale also play a significant role in driving the move towards in-house manufacturing. In addition, advancements in manufacturing technologies and processes are making in-house production more feasible and cost-effective, even for smaller biotech companies.

On the contrary, the market drivers for outsourced manufacturing in the mRNA vaccines and therapeutics industry are predominantly shaped by the rapid advancement in biotechnologies, coupled with the global urgency to respond to emerging health crises. One key market driver is the need for speed and scalability in vaccine production to meet global demand, particularly in times of health crises. Outsourced manufacturing allows for quicker ramp-up of production capacity.

Additionally, the complexity and specialized requirements of mRNA vaccine production, including high-precision cold-chain logistics and proprietary lipid nanoparticle technology, demand a level of expertise that not all pharmaceutical companies possess. This drives the demand for specialized contract manufacturing organizations (CMOs) that have the necessary technology and know-how.

Breakup by Application:

  • Cancer
  • Infectious Disease
  • Gene Editing
  • Protein Replacemen.

Infectious disease dominate the market

The mRNA vaccines and therapeutics industry for infectious diseases is majorly influenced by the unprecedented global demand for effective vaccines to combat emergent infectious diseases. This is largely due to the unique ability of mRNA vaccines to be rapidly designed and produced in response to new viral threats. Furthermore, the relatively high efficacy and favorable safety profile of approved mRNA vaccines, such as those from Moderna and Pfizer-BioNTech, is supporting the confidence in this innovative technology.

On the other hand, the cancer application is driven due to the growing global burden of cancer, with increasing incidence rates across various age groups. Along with this, the growing need for effective treatments is propelling research and innovation in mRNA therapeutics. mRNA vaccines have gained substantial attention due to their success in tackling infectious diseases. Technological advancements in bioinformatics and nanotechnology enable the fine-tuning of mRNA vaccines for cancer-specific antigens, further driving this market.

Breakup by End-User:

  • Hospitals and Clinics
  • Research Organizations
  • Other.

Hospitals and clinics dominate the market

Numerous factors for hospitals and clinics end-user in the mRNA vaccines and therapeutics industry includes the necessity for efficient, fast-developing vaccines to combat existing and emerging infectious diseases, which was underscored by the successful implementation of mRNA technology. Along with this, the increasing prevalence of cancer and genetic diseases also raises the demand, as mRNA therapeutics provide innovative, personalized treatment approaches. Additionally, the growing awareness and acceptance of mRNA vaccines and therapeutics among medical practitioners and patients also contributes to this growth.

The market drivers for research organizations in the mRNA vaccines and therapeutics industry are largely defined by the growing prevalence of infectious diseases and cancers, increased investment in R&D, and rapid advancements in biotechnology. Additionally, the shifting preference towards personalized medicine, with mRNA therapeutics playing a critical role in this evolution. Governmental support and funding for mRNA research, coupled with a strong pipeline of mRNA-based therapeutics and vaccines in clinical trials, are also significant market drivers.

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Afric.

Europe exhibits a clear dominance, accounting for the largest market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, United Kingdom, France, Italy, Spain, Russia and others); Asia Pacific (Japan, China, Australia, South Korea, India, Indonesia and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.

The mRNA vaccines and therapeutics industry in Europe is driven by ongoing investment in research and development fuels the expansion of the mRNA portfolio beyond vaccines into potential cures for cancer, genetic diseases, and other chronic conditions, further propelling the market growth. The presence of seamless approval processes, implemented during the pandemic, also act as a catalyst, facilitating quicker route-to-market and uptake for novel mRNA products. Moreover, the strong presence of key industry players in the region, underpin the robust growth of the mRNA vaccines and therapeutics market.

On the contrary, Asia Pacific is estimated to expand further in this domain due to the rising prevalence of infectious diseases, and the increased awareness of the need for preventative measures. Technological advancements are also key, as growing research and development capabilities in countries, such as China and India are accelerating the pace of innovative mRNA therapeutics. Additionally, the region's large population base provides a massive potential demand for these vaccines.

Competitive Landscape:

The global mRNA vaccines and therapeutics market is experiencing significant growth due to the increasing investments in research and development (R&D) to create more effective vaccines and therapeutics, as well as to expand the use of mRNA technology beyond vaccines to a broader range of therapeutic applications, including cancer treatment, cardiovascular diseases, and genetic disorders. Along with this, companies are forging partnerships and collaborations with academic institutions, biotech firms, and other pharmaceutical companies to accelerate the development of mRNA vaccines and therapeutics. This approach helps to pool resources, share knowledge, and diversify risk.

In addition, companies are working closely with regulatory bodies across the globe to ensure their products meet safety and efficacy requirements. They are conducting extensive clinical trials and are in constant communication with authorities to secure approvals for their products. Furthermore, companies are also investing in efforts to educate the public about the safety and efficacy of mRNA vaccines, to overcome vaccine hesitancy and misinformation.

The report has provided a comprehensive analysis of the competitive landscape in the global mRNA vaccines and therapeutics market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • Arcturus Therapeutics Inc.
  • BioNTech SE
  • CureVac AG
  • eTheRNA immunotherapies NV
  • ethris GmbH
  • GlaxoSmithKline PLC
  • Moderna Therapeutics Inc.
  • Translate Bio Inc.
  • Argos Therapeutics, Inc.
  • Sangamo Therapeutics Inc.
  • Pfizer Inc.

Key Questions Answered in This Report

  • What was the size of the global mRNA vaccines and therapeutics market in 2025?
  • What is the expected growth rate of the global mRNA vaccines and therapeutics market during 2026-2034?
  • What are the key factors driving the global mRNA vaccines and therapeutics market?
  • What has been the impact of COVID-19 on the global mRNA vaccines and therapeutics market?
  • What is the breakup of the global mRNA vaccines and therapeutics market based on the vaccine type?
  • What is the breakup of the global mRNA vaccines and therapeutics market based on the treatment type?
  • What is the breakup of the global mRNA vaccines and therapeutics market based on vaccine manufacturing?
  • What is the breakup of the global mRNA vaccines and therapeutics market based on the application?
  • What is the breakup of the global mRNA vaccines and therapeutics market based on the end-user?
  • What are the key regions in the global mRNA vaccines and therapeutics market?
  • Who are the key players/companies in the global mRNA vaccines and therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Introduction to mRNA Vaccines and Therapeutics

  • 5.1 History of mRNA Vaccines and Therapeutics Development
  • 5.2 Incidence and Prevalence of Chronic Diseases and Major Infectious Diseases
  • 5.3 Prevention and Treatment Using mRNA Vaccines and Therapeutics
    • 5.3.1 mRNA Modifications
    • 5.3.2 mRNA Efficiencies
    • 5.3.3 Adjuvant/Stimulant and Carrier Technologies for mRNA-Based Vaccines
    • 5.3.4 Carriers for mRNA-Based Protein and Antibody Therapeutics

6 Global mRNA Vaccines and Therapeutics Market

  • 6.1 Market Potential Overview
  • 6.2 Market Potential
  • 6.3 Impact of COVID-19
  • 6.4 mRNA Vaccines in Pipeline

7 Market Breakup by Vaccine Type

  • 7.1 Self-amplifying mRNA-Based Vaccines
  • 7.2 Conventional Non-Amplifying mRNA-Based Vaccines

8 Market Breakup by Treatment Type

  • 8.1 Gene Therapy
  • 8.2 Monoclonal Antibody
  • 8.3 Gene Transcription
  • 8.4 Cell Therapy
  • 8.5 Bioengineered Vaccine
  • 8.6 Others

9 Market Breakup by Vaccine Manufacturing

  • 9.1 In-House
  • 9.2 Out-Sourced

10 Market Breakup by Application

  • 10.1 Cancer
  • 10.2 Infectious Disease
  • 10.3 Gene Editing
  • 10.4 Protein Replacement

11 Market Breakup by End-User

  • 11.1 Hospitals and Clinics
  • 11.2 Research Organizations
  • 11.3 Others

12 Market Breakup by Region

  • 12.1 North America
    • 12.1.1 Market Breakup by Country
      • 12.1.1.1 United States
      • 12.1.1.2 Canada
  • 12.2 Europe
    • 12.2.1 Market Breakup by Country
      • 12.2.1.1 Germany
      • 12.2.1.2 United Kingdom
      • 12.2.1.3 France
      • 12.2.1.4 Italy
      • 12.2.1.5 Spain
      • 12.2.1.6 Russia
      • 12.2.1.7 Others
  • 12.3 Asia Pacific
    • 12.3.1 Market Breakup by Country
      • 12.3.1.1 Japan
      • 12.3.1.2 China
      • 12.3.1.3 Australia
      • 12.3.1.4 South Korea
      • 12.3.1.5 India
      • 12.3.1.6 Indonesia
      • 12.3.1.7 Others
  • 12.4 Latin America
    • 12.4.1 Market Breakup by Country
      • 12.4.1.1 Brazil
      • 12.4.1.2 Mexico
      • 12.4.1.3 Others
  • 12.5 Middle East and Africa
    • 12.5.1 Market Breakup by Country

13 SWOT Analysis

  • 13.1 Overview
  • 13.2 Strengths
  • 13.3 Weaknesses
  • 13.4 Opportunities
  • 13.5 Threats

14 Value Chain Analysis

15 Porters Five Forces Analysis

  • 15.1 Overview
  • 15.2 Bargaining Power of Buyers
  • 15.3 Bargaining Power of Suppliers
  • 15.4 Degree of Competition
  • 15.5 Threat of New Entrants
  • 15.6 Threat of Substitutes

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 Moderna, Inc.
      • 16.3.1.1 Business Overview
      • 16.3.1.2 Products Offered
      • 16.3.1.3 Business Strategies
      • 16.3.1.4 SWOT Analysis
      • 16.3.1.5 Major News and Events
    • 16.3.2 BioNTech SE
      • 16.3.2.1 Business Overview
      • 16.3.2.2 Products Offered
      • 16.3.2.3 Business Strategies
      • 16.3.2.4 SWOT Analysis
      • 16.3.2.5 Major News and Events
    • 16.3.3 Pfizer Inc.
      • 16.3.3.1 Business Overview
      • 16.3.3.2 Products Offered
      • 16.3.3.3 Business Strategies
      • 16.3.3.4 SWOT Analysis
      • 16.3.3.5 Major News and Events
    • 16.3.4 GSK plc
      • 16.3.4.1 Business Overview
      • 16.3.4.2 Products Offered
      • 16.3.4.3 Business Strategies
      • 16.3.4.4 SWOT Analysis
      • 16.3.4.5 Major News and Events
    • 16.3.5 Arcturus Therapeutics
      • 16.3.5.1 Business Overview
      • 16.3.5.2 Products Offered
      • 16.3.5.3 Business Strategies
      • 16.3.5.4 SWOT Analysis
      • 16.3.5.5 Major News and Events
    • 16.3.6 Sanofi
      • 16.3.6.1 Business Overview
      • 16.3.6.2 Products Offered
      • 16.3.6.3 Business Strategies
      • 16.3.6.4 SWOT Analysis
      • 16.3.6.5 Major News and Events
    • 16.3.7 Merck & Co.
      • 16.3.7.1 Business Overview
      • 16.3.7.2 Products Offered
      • 16.3.7.3 Business Strategies
      • 16.3.7.4 SWOT Analysis
      • 16.3.7.5 Major News and Events

List of Figures

  • Figure 1: Global: mRNA Vaccines and Therapeutics Market Potential: Value Trends (in Billion USD), 2026-2034
  • Figure 2: Global: mRNA Vaccines and Therapeutics Market Potential (Self-amplifying mRNA-Based Vaccines): Value Trends (in Billion USD), 2026-2034
  • Figure 3: Global: mRNA Vaccines and Therapeutics Market Potential (Conventional Non-Amplifying mRNA-Based Vaccines): Value Trends (in Billion USD), 2026-2034
  • Figure 4: Global: mRNA Vaccines and Therapeutics Market Potential (Gene Therapy): Value Trends (in Billion USD), 2026-2034
  • Figure 5: Global: mRNA Vaccines and Therapeutics Market Potential (Monoclonal Antibody): Value Trends (in Billion USD), 2026-2034
  • Figure 6: Global: mRNA Vaccines and Therapeutics Market Potential (Gene Transcription): Value Trends (in Billion USD), 2026-2034
  • Figure 7: Global: mRNA Vaccines and Therapeutics Market Potential (Cell Therapy): Value Trends (in Billion USD), 2026-2034
  • Figure 8: Global: mRNA Vaccines and Therapeutics Market Potential (Bioengineered Vaccine): Value Trends (in Billion USD), 2026-2034
  • Figure 9: Global: mRNA Vaccines and Therapeutics Market Potential (Other Treatment Types): Value Trends (in Billion USD), 2026-2034
  • Figure 10: Global: mRNA Vaccines and Therapeutics Market Potential (In-House): Value Trends (in Billion USD), 2026-2034
  • Figure 11: Global: mRNA Vaccines and Therapeutics Market Potential (Out-Sourced): Value Trends (in Billion USD), 2026-2034
  • Figure 12: Global: mRNA Vaccines and Therapeutics Market Potential (Cancer): Value Trends (in Billion USD), 2026-2034
  • Figure 13: Global: mRNA Vaccines and Therapeutics Market Potential (Infectious Disease): Value Trends (in Billion USD), 2026-2034
  • Figure 14: Global: mRNA Vaccines and Therapeutics Market Potential (Gene Editing): Value Trends (in Billion USD), 2026-2034
  • Figure 15: Global: mRNA Vaccines and Therapeutics Market Potential (Protein Replacement): Value Trends (in Billion USD), 2026-2034
  • Figure 16: Global: mRNA Vaccines and Therapeutics Market Potential (Hospitals and Clinics): Value Trends (in Billion USD), 2026-2034
  • Figure 17: Global: mRNA Vaccines and Therapeutics Market Potential (Research Organizations): Value Trends (in Billion USD), 2026-2034
  • Figure 18: Global: mRNA Vaccines and Therapeutics Market Potential (Other End-Users): Value Trends (in Billion USD), 2026-2034
  • Figure 19: North America: mRNA Vaccines and Therapeutics Market Potential: Value Trends (in Billion USD), 2026-2034
  • Figure 20: North America: mRNA Vaccines and Therapeutics Market Potential: Breakup by Country (in %), 2025
  • Figure 21: United States: mRNA Vaccines and Therapeutics Market Potential: Value Trends (in Million USD), 2026-2034
  • Figure 22: Canada: mRNA Vaccines and Therapeutics Market Potential: Value Trends (in Million USD), 2026-2034
  • Figure 23: Europe: mRNA Vaccines and Therapeutics Market Potential: Value Trends (in Billion USD), 2026-2034
  • Figure 24: Europe: mRNA Vaccines and Therapeutics Market Potential: Breakup by Country (in %), 2025
  • Figure 25: Germany: mRNA Vaccines and Therapeutics Market Potential: Value Trends (in Million USD), 2026-2034
  • Figure 26: United Kingdom: mRNA Vaccines and Therapeutics Market Potential: Value Trends (in Million USD), 2026-2034
  • Figure 27: France: mRNA Vaccines and Therapeutics Market Potential: Value Trends (in Million USD), 2026-2034
  • Figure 28: Italy: mRNA Vaccines and Therapeutics Market Potential: Value Trends (in Million USD), 2026-2034
  • Figure 29: Spain: mRNA Vaccines and Therapeutics Market Potential: Value Trends (in Million USD), 2026-2034
  • Figure 30: Russia: mRNA Vaccines and Therapeutics Market Potential: Value Trends (in Million USD), 2026-2034
  • Figure 31: Others: mRNA Vaccines and Therapeutics Market Potential: Value Trends (in Million USD), 2026-2034
  • Figure 32: Asia Pacific: mRNA Vaccines and Therapeutics Market Potential: Value Trends (in Billion USD), 2026-2034
  • Figure 33: Asia Pacific: mRNA Vaccines and Therapeutics Market Potential: Breakup by Country (in %), 2025
  • Figure 34: Japan: mRNA Vaccines and Therapeutics Market Potential: Value Trends (in Million USD), 2026-2034
  • Figure 35: China: mRNA Vaccines and Therapeutics Market Potential: Value Trends (in Million USD), 2026-2034
  • Figure 36: Australia: mRNA Vaccines and Therapeutics Market Potential: Value Trends (in Million USD), 2026-2034
  • Figure 37: South Korea: mRNA Vaccines and Therapeutics Market Potential: Value Trends (in Million USD), 2026-2034
  • Figure 38: India: mRNA Vaccines and Therapeutics Market Potential: Value Trends (in Million USD), 2026-2034
  • Figure 39: Indonesia: mRNA Vaccines and Therapeutics Market Potential: Value Trends (in Million USD), 2026-2034
  • Figure 40: Others: mRNA Vaccines and Therapeutics Market Potential: Value Trends (in Million USD), 2026-2034
  • Figure 41: Latin America: mRNA Vaccines and Therapeutics Market Potential: Value Trends (in Billion USD), 2026-2034
  • Figure 42: Latin America: mRNA Vaccines and Therapeutics Market Potential: Breakup by Country (in %), 2025
  • Figure 43: Brazil: mRNA Vaccines and Therapeutics Market Potential: Value Trends (in Million USD), 2026-2034
  • Figure 44: Mexico: mRNA Vaccines and Therapeutics Market Potential: Value Trends (in Million USD), 2026-2034
  • Figure 45: Others: mRNA Vaccines and Therapeutics Market Potential: Value Trends (in Million USD), 2026-2034
  • Figure 46: Middle East and Africa: mRNA Vaccines and Therapeutics Market Potential: Value Trends (in Billion USD), 2026-2034
  • Figure 47: Middle East and Africa: mRNA Vaccines and Therapeutics Market Potential: Breakup by Country (in %), 2025
  • Figure 48: Global: mRNA Vaccines and Therapeutics Industry: SWOT Analysis
  • Figure 49: Global: mRNA Vaccines and Therapeutics Industry: Value Chain Analysis
  • Figure 50: Global: mRNA Vaccines and Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: mRNA Vaccines and Therapeutics Market Potential: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: mRNA Vaccines and Therapeutics Market: List of Pipeline mRNA Vaccines
  • Table 3: Global: mRNA Vaccines and Therapeutics Market Potential: Breakup by Vaccine Type (in Billion USD), 2026-2034
  • Table 4: Global: mRNA Vaccines and Therapeutics Market Potential: Breakup by Treatment Type (in Billion USD), 2026-2034
  • Table 5: Global: mRNA Vaccines and Therapeutics Market Potential: Breakup by Vaccine Manufacturing (in Billion USD), 2026-2034
  • Table 6: Global: mRNA Vaccines and Therapeutics Market Potential: Breakup by Application (in Billion USD), 2026-2034
  • Table 7: Global: mRNA Vaccines and Therapeutics Market Potential: Breakup by End-User (in Billion USD), 2026-2034
  • Table 8: Global: mRNA Vaccines and Therapeutics Market Potential: Breakup by Region (in Billion USD), 2026-2034
  • Table 9: Global: mRNA Vaccines and Therapeutics Market: Competitive Structure
  • Table 10: Global: mRNA Vaccines and Therapeutics Market: List of Key Players